|
Prior to joining Ambrx, Inc., Dr. Kaldor served as President and CSO of Takeda San Diego Inc., the US Discovery Research Center for Takeda Pharmaceuticals. He instigated and led the March 2005 $270MM acquisition of Syrrx Inc. by Takeda that resulted in the creation of Takeda San Diego. Dr. Kaldor ran Syrrx, a privately held, structure-based drug discovery company, as its President and CSO from 2003 -2005. Syrrx built a robust portfolio of metabolic diseases and oncology clinical candidates during his tenure including SYR-322 (Alogliptin), a dipeptidyl peptidase 4 inhibitor for the treatment of diabetes now in Phase III clinical trials. Prior to joining Syrrx, Dr. Kaldor gained over 12 years of drug discovery and development experience at Eli Lilly and Company, as both a researcher and Director with line management responsibility for groups of up to 270 people. He received his formal education in organic chemistry at Harvard University, (Ph.D., 1989) and Columbia University, (B.S., 1984). Dr. Kaldor is the co-inventor of multiple compounds that have advanced into the clinic including ViraceptTM, a marketed HIV protease inhibitor. | 